Compounds of the formula I
in which R
1
and R
2
have the meanings indicated in Claim
1
, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
公式I中,其中R1和R2的含义如权利要求1所示的化合物是GCN2的抑制剂,可用于治疗癌症等疾病。
Triazolo[4,5-d]pyrimidine derivatives
申请人:Merck Patent GmbH
公开号:US09409914B2
公开(公告)日:2016-08-09
Compounds of the formula I
in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
公式I的化合物,其中R1和R2的含义如权利要求1所示,是GCN2的抑制剂,可用于治疗癌症等疾病。
US9409914B2
申请人:——
公开号:US9409914B2
公开(公告)日:2016-08-09
[EN] HETEROCYCLIC GCN2 MODULATORS<br/>[FR] MODULATEURS DE GCN2 HÉTÉROCYCLIQUES
申请人:HIBERCELL INC
公开号:WO2021222147A1
公开(公告)日:2021-11-04
The invention relates to methods of using modulators of GCN2 and compositions thereof, in the treatment of cancers and other diseases and disorders associated with GCN2 activation, said modulators having the Formulae I, II, III, IV, V, VI, VII, and/or VIII.
[EN] TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZOLO[4,5-D]PYRIMIDINE
申请人:MERCK PATENT GMBH
公开号:WO2013110309A1
公开(公告)日:2013-08-01
Compounds of the formula (I) in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.